Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

• ClinicalTrials.gov Identifier: NCT03635879
• Recruitment Status: Withdrawn
• First Posted: August 17, 2018
• Last Update Posted: September 27, 2018
• Sponsor: Cerecin
• Information provided by (Responsible Party): Cerecin

Study Description

Brief Summary:

This is a Phase I, open label, randomized, 6-way crossover, pilot PK study

Condition or disease	Intervention/treatment	Phase
Alzheimer Disease	Other: MCTprocal medical food; Other: Milk/tricaprilin oil blend; Other: AC-1207; Other: AC-1205; Other: AC-1206; Drug: AC-1202	Phase 1

Detailed Description:

12 healthy, male subjects enrolled, subject will be randomized to receive a single dose of one of six treatment, with a 2 day washout in between each dosing period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: A Phase 1, Single-Center, Pilot, Single-Dose, 6-Way Crossover Study to Compare Six Formulations of Medium Chain Triglycerides on the Pharmacokinetics of Ketone Body Production
• Estimated Study Start Date: February 13, 2019
• Estimated Primary Completion Date: April 16, 2019
• Estimated Study Completion Date: April 16, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: MCTprocal medical food; Vitaflo MCTprocal, single dose (20 g MCT)	Other: MCTprocal medical food; 32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Active Comparator: Milk/tricaprilin oil blend; Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)	Other: Milk/tricaprilin oil blend; 154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
Active Comparator: AC-1207; AC-1207 liquid, single dose (20 g tricaprilin)	Other: AC-1207; AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Active Comparator: AC-1205; AC-1205 liquid, single dose (20 g tricaprilin)	Other: AC-1205; AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Active Comparator: AC-1206; AC-1206 liquid, single dose (20 g tricaprilin)	Other: AC-1206; AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
Experimental: AC-1202; AC-1206 liquid, single dose (20 g tricaprilin)	Drug: AC-1202; AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1

Outcome Measures

Primary Outcome Measures :

1. Total ketones [ Time Frame: 1 day ]
   Area Under the Curve (AUC) AUC 0 - last
2. Total ketones [ Time Frame: 1 day ]
   AUC 0 - 4
3. Total ketones [ Time Frame: 1 day ]
   AUC 0 - 6
4. Total ketones [ Time Frame: 1 day ]
   AUC 0 - 8
5. Total ketones [ Time Frame: 1 day ]
   Maximum Plasma Concentration (Cmax)
6. B-hydroxybutyrate [ Time Frame: 1 day ]
   AUC 0 - last
7. B-hydroxybutyrate [ Time Frame: 1 day ]
   AUC 0 - 4
8. B-hydroxybutyrate [ Time Frame: 1 day ]
   AUC 0 - 6
9. B-hydroxybutyrate [ Time Frame: 1 day ]
   AUC 0 - 8
10. B-hydroxybutyrate [ Time Frame: 1 day ]
    Cmax
11. Acetoacetate [ Time Frame: 1 day ]
    AUC 0 - last
12. Acetoacetate [ Time Frame: 1 day ]
    AUC 0 - 4
13. Acetoacetate [ Time Frame: 1 day ]
    AUC 0 - 6
14. Acetoacetate [ Time Frame: 1 day ]
    AUC 0 - 8
15. Acetoacetate [ Time Frame: 1 day ]
    Cmax

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Healthy, adult, male 18 55 years of age, inclusive, at Screening.
2. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study based on self-reporting.
3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ the upper limit of normal and triglyceride levels must be < 250 mg/dL.
5. Hemoglobin levels ≥ the lower limit of normal at Screening and Day -1 of Period 1.
6. A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
7. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria:

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past year prior to Day -1 of Period 1.
5. History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
6. History or presence of symptomatic diverticular disease, uncontrolled gastroesophageal reflux disease, ulcers, inflammatory bowel disease, irritable bowel syndrome or recurrent diarrhea, or gout.
7. Positive urine drug results at Screening or Check-in.
8. Positive alcohol results at Screening or Check-in. One repeat assessment is permitted.
9. Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening. One repeat assessment is permitted.
11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at Screening.
12. QTcF interval is >460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at Screening.
13. Estimated creatinine clearance ≤ 80 mL/min at Screening.
14. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hours) may be permitted during the study.
15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
16. Has been following a ketogenic diet, in the opinion of the PI or designee, within 2 weeks prior to Day -1 of Period 1.
17. Is lactose intolerant.
18. Is unable to complete the standard breakfast prior to dosing on Day 1 of each Period.
19. Donation of blood or significant blood loss within 56 days prior to Day -1 of Period 1.
20. Plasma donation within 7 days prior to Day -1 of Period 1.
21. Participation in another clinical study within 28 days prior to Day -1 of Period 1. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Cerecin
• ClinicalTrials.gov Identifier: NCT03635879
• Other Study ID Numbers: AX-18-018_PK
• First Posted: August 17, 2018
• Last Update Posted: September 27, 2018
• Last Verified: September 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders